Belluscura Share Discussion Threads

[buywell3] 04/9/2021 16:27

Production is only just starting to meet initial orders placed by the 4 USA Distributors recently signed up

Monday is all about the outlook statement and plans for 2022 when production ramps up to meet demand and new larger POC models are put into production plus other new products

[pngasef] 04/9/2021 12:34

What to expect from the results on Monday? Chunky growing sales, profit forecasts smashed, new sales agreements, broker upgrades. Here's hoping for a stellar share price performance.

[maytrees] 02/9/2021 10:31

Interesting that in a morning of sells the BELL bid share price gains slightly.
Perhaps good results in prospect?

[buywell2] 31/8/2021 06:55

POST REMOVED

[netcurtains] 24/8/2021 14:36

Whoops thats torn it.
😃

[buywell2] 23/8/2021 21:00

POST REMOVED

[maytrees] 23/8/2021 08:12

Good morning

Any reason for the 8% gain today so far I wonder.
More sells now than buys but I am happy to hold.

[buywell3] 20/8/2021 20:38

stuffee

See

4 Manufacturing



Depends how you read this

The two manufacturers imo are one related to batteries and the other to the unit and zeolite cartridge


So the way buywell reads this is that there in one company that makes the complete unit itself and another that just makes the batteries so yes agreed there are two outsourced American companies

Which was fine when first planned prior to floatation BUT my point now is that things have changed with Delta and demand is soaring and will keep on soaring as survivors suffer long COVID symptoms and require home oxygen therapy --- plus another variant is on the way

So things might be all well and good as long as the Unit/Zeolite manufacturer is big enough and has the capacity to gear up to meet increased orders quickly

One would imagine that the US new Distributors are chomping at the bit

Also what about all the new products that are being developed --- will this same chosen company make all of those also ?

Eggs and baskets come to mind --- buywell is a very cautious and questioning avatar

Personally buywell thinks it would be a good idea to spread units production between two manufacturers just in case --- likewise batteries

Comes under Risk Management

The chart speaks volumes and the market loves the company --- this post is NOT a criticism merely a respectful suggestion

buywell hates not making hay(money) whilst the sun shines (orders)

Pedal to the metal time

IMHO the market would absolutely LOVE further expansion of manufacturing plans at the moment

dyor imo

[netcurtains] 20/8/2021 16:05

Interesting finish.

[hedgehog 100] 20/8/2021 12:44

"A smart technology play offering material upside

A little known small-cap investment company focused on high growth technologies in food technology, autonomous vehicles, smart eyewear and respiratory medical devices has delivered eye-catching valuation gains.

August 19, 2021
By Simon Thompson

• NAV surges 56 per cent to US$51m in latest six-month period.
• Value of 15 per cent stake in Belluscura has since soared 70 per cent to £15.4m since the half year-end.
• Portfolio company, Lucyd, launches crowdfunding at double Tek’s pre-money valuation in its interim accounts.

TekCapital (TEK:22.25p), a £29.1m market capitalisation company that holds a concentrated investment portfolio focused on high growth technologies in the food technology, autonomous vehicles, smart eyewear and respiratory medical devices, has released eye-catching interim results.

Net asset value (NAV) surged 56 per cent to US$51.1m (39c a share) in the six months to 31 May 2021, buoyed by a thumping US$8.6m (£6.2m) paper gain on Tek’s pre-IPO holding of 17.1m shares in recently floated Belluscura (BELL: 90p), an Aim-traded company that is developing and commercialising IP in the medical devices space. Belluscura's first product, the X-PLO₂RTM, is a lightweight FDA cleared portable oxygen concentrator (POC) that has been designed to replace larger, metal oxygen tanks and heavier POC devices. Weighing less than 1.5kg, it is the world's first modular POC and generates more oxygen by weight than any other FDA cleared POC in its class.

The World Health Organisation (WHO) estimate that 328m people globally have Chronic Obstructive Pulmonary Disease (COPD), of whom 65m have moderate or severe symptoms and 90 per cent are typically middle-aged or older adults who smoke. COPD is the third leading cause of death in the world, symptoms being breathlessness, a persistent chesty cough, frequent chest infections and persistent wheezing.

Analysts estimate the POC market could be worth US$2.4bn (£1.75bn) within three years, up from US$1.66bn in 2020, a high growth market and one that is growing even faster due to Covid-19. Indeed, WHO plans to purchase 184,000 units at a cost of over US$100m to distribute worldwide, having so far distributed over 30,000 concentrators and 40,000 pulse oximeters and patient monitors across 121 countries.

The medical portable O2 market is expected to grow to US$2.4bn by 2024
2018 2019 2020 2021E 2022E 2023E 2024E
Revenue $1.40bn $1.51bn $1.66bn $1.83bn $2.01bn $2.21bn $2.41bn
Source: Global Insights

Importantly, X-PLO₂RTM offers cost benefits to users, too. That’s because they can swap out the filter cartridges to enable higher capacity oxygen flow without having to buy a new device; like upgrading memory on a laptop. The result is significantly more affordable oxygen therapy for the life of the patient. Belluscura's management team plan to spend £3m of the £17.5m proceeds raised in May’s IPO launching X-PLO₂R – the first units will be distributed before the end of September and the company has four distribution agreements in place across East and MidWest America. A further £8m is earmarked to progress additional products within the range for launch later this year and early in 2022.

Investors have been cottoning onto Belluscura's progress, hence why its share price has soared 70 per cent from 53p to 90p since Tek’s half year-end, the effect of which is to add a further US$8.3m (6.3c a share) to the company’s NAV. ...

Tek’s 15 per cent stake in Belluscura is now worth £15.4m, or more than half Tek’s own market capitalisation of £28.8m. There is ample scope for further valuation gains, too. That’s because Belluscura's house broker Dowgate Capital believes that by 2023 the £103m market capitalisation company will reach profitability and be cashflow positive based on 12,000 units sales. Having hit that inflexion point, analysts are predicting the company could be selling 22,000 units (based on 5 per cent share of the POC market) in 2024 to produce revenue of US$47.9m, cash profit of US$11.4m and earnings per share (EPS) of 6.5p. With gross margin around 50 per cent, the operational gearing of the business is such that profits and EPS would treble in 2025 based on 50,000 unit sales.

Belluscura financial forecasts 2021 to 2025
2021E 2022E 2023E 2024E 2025E
Units sold 150 2,000 12,000 22,000 50,000
Revenue $0.2m $3.0m $19.8m $47.9m $109.9m
Ebitda -$2.3m -$4.6m $1.1m $11.4m $33.5m
EPS na na 0.1p 6.5p 18.2p
PE na na na 8 3
Net cash $17.4m $9.8m $7.9m $17.3m $44.6m
Source: Dowgate Capital (27 July 2021) ..."

[maytrees] 20/8/2021 09:34

Good morning
TEK share price is now catching up though that may be more down to comment in IC.

[stuffee] 20/8/2021 08:55

Buywell,

I thought Bell had subcontracted all manufacturing to various specialist US manufacturers, as mentioned in my post, number 11 of 11 June, so presumably can gear up production relatively quickly without needing significant further funds.

I did suggest in this post that Bell had all the prospects to become at least a five bagger, (reaching 300p+). Its price performance to date suggests it is well on track.

[buywell3] 20/8/2021 02:32

Dear Boris

In America cases in children have risen substantially since the beginning of July and now account for 18% of newly confirmed weekly cases, leading to more hospitalizations.
This will happen in the UK now as they remain unvaccinated and unprotected

Air Purifiers fitted with internal UVC LED killing chambers in schools is a MUST

HEPA medical grade HEP14 the highest available HEPA filter will NOT stop the
SARS-CoV-2 virus because it is too small

check buywells posts on the advfn BUY thread for elucidation and enlightenment



regards
buywell

[netcurtains] 19/8/2021 09:27

I don't normally agree with buywell (he hated my Triad shares) however on this instance I think BELL could stand outside chance of being the UKs new BOC (sold to the Germans about 20 years go - before that it was a FTSE100 company).

Anyway I have a tiny few. No idea what will happen so did not get too many.

[buywell3] 19/8/2021 07:44

The only problem as buywell sees it

Is that Belluscura could have difficulty filling all the orders that must be coming in
at the moment

This being in America , where Covid case numbers have recently rocketed 700% in a week

The DELTA variant seems to be having a much greater impact over in the US than in the UK at the moment

Perhaps one way of scaling up production quickly would be to license BELL technology to a suitably approved/certified/experienced American engineering company that has undertaken similar work and can hit the road running

[maytrees] 18/8/2021 12:14

Good afternoon
Even comparatively small trades seem to move the share price - up at present.

[hedgehog 100] 16/8/2021 17:41

Also from the Belluscura AIM admission document, 24 May 2021 -

"Stationary Oxygen Concentrators

Although the global Stationary Oxygen Concentrator market is dominated by the same players as the Portable Oxygen Concentrator market, they have smaller market shares, with the four major groups only accounting for 41 per cent. of the market.

The largest player is Respironics (Philips Healthcare) with 15 per cent., followed by Invacare with 10 per cent., Inogen with 9 per cent. and CAIRE with 7 per cent.. The 59 per cent. balance of the market is broadly spread across other device manufacturers.

Stationary Concentrators are, by nature, large and heavy. With Belluscura’s advanced Technology enabling it to make devices smaller and lighter the Directors believe the Group can make inroads into this market."

[hedgehog 100] 16/8/2021 17:08

More from the Belluscura AIM admission document, 24 May 2021 -

"Future Opportunities

Biometric Drug & Device Data

The Directors believe that following the launches of the products above, there is a significant opportunity to enhance these devices by collecting and collating Smart data.
Through the integration of biometric data from smart devices, Belluscura would be able to collate valuable clinical data to aid patients’ clinicians to better understand the use of the device and in turn allow clinicians to better assess their patients’ changing needs.

Integration possibilities include:

GPS Smart Watch Activity, movement, location, altitude, heart rate, stress levels, sleep patterns

Smart Pulse Oximeter Blood saturation - SaO2

Smart Inhaler Providing medication information

X-PLO2R (with Bluetooth) Oxygen flow setting and breathing rate

Collecting this information through a Belluscura COPD App the Company should be able to provide a fuller overall picture of a patient’s circumstances, activity and functionality to the clinician, making the X-PLO2R range of products a more valuable proposition.

Devices beyond X-PLO2R

Belluscura also has three further products in development, which utilise the same technology as the X-PLO2R but for larger units:

HO2ME HO2ME is a prototype of the X-PLO2R but is stationary and for home use. HO2ME is expected to be able to deliver 5-10L of continuous oxygen and is intended for Stage 4 COPD patients.

VENTO2LAT-R A non-invasive portable ventilator.

ECMO2 Device Extra-Corporeal Membrane Oxygen (“ECMO”) has for many years been used for patients with life-threatening hypoxaemia and hypercarbia. Positive outcomes by patients who suffered from SARS or Swine Flu has resulted in ECMO becoming a recommended treatment for patients with severe acute respiratory distress syndrome. Belluscura is developing a portable ECMO product (“ECMO2”) to serve this market."

[hedgehog 100] 16/8/2021 16:37

From the Belluscura AIM admission document, 24 May 2021 -

"3. THE TECHNOLOGY

The X-PLO2R is designed utilising patented advanced molecular oxygen enrichment technologies. The Group owns or licenses 26 patents and pending applications for its oxygen enrichment technologies that centre on making oxygen concentrators smaller, lighter and quieter than current products on sale. Belluscura highlights four key advantages of its range of oxygen concentrators.

• Advanced zeolite Technology

Belluscura’s oxygen concentrators take in air and pass it through a sieve bed that contains zeolites. When subjected to a high pressure, zeolites have an affinity for Nitrogen, and the Nitrogen molecules temporarily bind to the zeolites, allowing the oxygen to pass through. Releasing the pressure unbinds the Nitrogen which is expelled back into the air. Whilst zeolite technology itself is not new, Belluscura has combined advanced zeolite technology with its other proprietary technology below to improve efficiency.

• Ultra-Rapid Pressure Swing Adsorption

Pressure swing adsorption (“PSA”) processes utilize the fact that under high pressure, gases tend to be attracted to solid surfaces, or 'adsorbed'. The higher the pressure, the more gas is adsorbed. When the pressure is reduced, the gas is released, or desorbed. PSA processes can be used to separate gases in a mixture because different gases tend to be attracted to different solid surfaces more or less strongly. If a gas mixture such as air is passed under pressure through a vessel containing an adsorbent bed of zeolite that attracts nitrogen more strongly than oxygen, part or all of the nitrogen will stay in the bed, and the gas exiting the vessel will be richer in oxygen than the mixture entering. When the bed reaches the end of its capacity to adsorb nitrogen, it can be regenerated by reducing the pressure, thus releasing the adsorbed nitrogen. It is then ready for another cycle of producing oxygen-enriched air. Belluscura’s technology enhances the processing speed allowing for greater oxygen flow.

• Modularity

Belluscura has developed and patented a modular system (“ModulAir” technology) that allows the device to be upgraded as the patient's disease progresses, but also enables the device to operate to different specifications enabling it to be used for multiple different purposes.
The X-PLO2R base unit provides 4L of Pulse Dose oxygen which is suitable for a COPD patient in Stage 3 of the disease. As the disease progresses, the patient will be able to upgrade to the X-PLO2R CX which is designed to provide 750ml Continuous Flow in addition to 4L of Pulse Dose. The advantage for the consumer is that they do not have to buy a new unit but can instead upgrade from an X-PLO2R to the X PLO2R CX. The same modular system will apply to the X-PLO2R DX where the base model is designed to provide 6L of Pulse Dose oxygen with the ability to be upgraded to both 8L of Pulse Dose oxygen and 2L of Continuous Flow oxygen.
By controlling X-PLO2R through specific Zeolite cartridges, the device is capable of running in multiple ways, allowing it to be tailored for specific purposes, for example, Sport/Recreational, Industrial, Altitude and Private Labelling. The ability to run multiple scenarios through one device eliminates the additional manufacturing costs of making multiple devices.

• Consumer replaceable

The X-PLO2R range of oxygen concentrators has patented consumer replaceable zeolite cartridge technology whereby the cartridge can be easily removed and replaced by the patient. Traditional oxygen concentrators have the zeolite filters built into the device and when the filter needs replacing the device needs to be returned to the supplier for the filter to be replaced. The POC provider may also have to send out a loaned POC for the consumer to use while their filter is replaced. X-PLO2R customers will simply contact Belluscura for a new sieve bed, which is sent to the customer and can be replaced in minutes.
As noted above, a key focus for clinicians treating patients with oxygen therapy is keeping patients mobile and active. In particular, size and weight of the oxygen concentrator are key considerations for the demographic of patients likely to be utilising these devices. By utilising its patented Ultra-Rapid Pressure Swing Adsorption, User Replaceable Sieve and ModulAir technologies, along with advanced molecular zeolites, Belluscura has created a much more energy efficient and adaptable product."

[hedgehog 100] 14/8/2021 18:38

BELL Technical Analysis from SwingTradeBot:

"Technical Analysis for BELL"

"ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up"

[hedgehog 100] 14/8/2021 12:26

BELL Technical Analysis from Investing.com:

"BELLB Technical Analysis"

"Summary: STRONG BUY
Moving Averages: BUY Buy (9) Sell (3)
Technical Indicators: STRONG BUY Buy (6) Sell (2)"

[hedgehog 100] 14/8/2021 10:43

BELL Technical Analysis from TradingView.com:

"BELLUSCURA PLC ORD 1P"

"Technical analysis"

"Oscillators Summary Moving Averages"

"NEUTRAL BUY STRONG BUY"

[buywell2] 13/8/2021 20:46

POST REMOVED